NCT05310032View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 21, 2022

Primary Completion Date

December 12, 2022

Study Completion Date

March 31, 2023

Conditions
Obesity
Interventions
DRUG

HSG4112

Once-daily oral adminstration

DRUG

Placebo

Once-daily oral adminstration

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Glaceum
All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

lead

Glaceum

INDUSTRY

NCT05310032 - A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses | Biotech Hunter | Biotech Hunter